Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SCD | O00767 | 4/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP1 | P63208 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345122 | 0.91 | CHRM4 (0.43) | CHRM4MEN1KMT2ASCDRET | |
| SCHEMBL345285 | 0.90 | CHRM4 (0.42) | CHRM4MEN1KMT2ARETPOLB | |
| SCHEMBL345267 | 0.90 | NPC1 (0.43) | CHRM4MEN1KMT2APOLBMAPT | |
| SCHEMBL345688 | 0.87 | FFAR4 (0.39) | CHRM4MEN1KMT2ASCDPOLB | |
| SCHEMBL343963 | 0.86 | MEN1 (0.37) | CHRM4MEN1KMT2AALDH1A1CKS1B | |
| SCHEMBL345088 | 0.86 | PDE10A (0.44) | MEN1KMT2ASCDALDH1A1 | |
| SCHEMBL2405683 | 0.85 | CHRM4 (0.41) | CHRM4SCDRETCKS1BSKP1 | |
| SCHEMBL345663 | 0.84 | CHRM4 (0.42) | CHRM4RETCKS1BSKP1SKP2 | |
| SCHEMBL2406377 | 0.81 | CHRM4 (0.41) | CHRM4RETCKS1BSKP1SKP2 | |
| SCHEMBL9993059 | 0.81 | RET (0.41) | MEN1KMT2ASCDRETALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716289-B2 | Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | CHRM4 1210/4885MEN1 812/4885KMT2A 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.